Hibiscus2 (Sickle Cell Disease) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called etavopivat (the study drug) is a safe and effective option for children and adolescents who have SCD.
Sickle Cell Disease (SCD)
Who Can Participate in the Study?
Children ages 12-17 who:
- Are diagnosed with SCD
- Have had at least 15 documented vaso-occlusive crises (pain crises)
For more information, contact the study team at morgan.low@duke.edu.
What is Involved?
If you and your child choose to take part in this study, they will get a random assignment (like a coin flip) to either:
- Take a 400mg dose of the study drug; OR
- Take a placebo (inactive substance with no drug in it)
Your child will take the study drug or placebo for 1 year. After this year is finished, you and they will have the option to continue on to Part 2 of the study. In Part 2, everyone will receive a 400mg dose of the study drug regardless of whether or not they took the study drug or placebo for the first year. Part 2 will also last for 1 year.
Study Details
